Analyst Research
| Report Title | Price |
|---|---|
|
Trading Report for (MDT). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
DOJ Closes Investigation Of Medtronic Inc's Infuse-Reuters
Reuters reported that the Department of Justice (DOJ) and the U.S. Attorney's Office have closed their investigation related to omission of safety issues of Medtronic Inc's controversial orthopedic product Infuse and its off-lable use. Infuse came under scrutiny after the influential Spine Journal noted that surgeons, who were paid tens of millions of dollars by Medtronic, failed to report serious complications from bioengineered bone-growth protein, including cancer, sterility in men and bone dissolution.
Latest Developments for Medtronic Inc
- Medtronic Inc Reaffirms FY 2013 Revenue Guidance-Conference Call
- Medtronic Inc Issues FY 2013 Revenue Guidance Above Analysts' Estimates; Reaffirms FY 2013 EPS Guidance-Conference Call
- Medtronic Inc Raises Low End Of Prior FY 2013 EPS Guidance To A Range Above Analysts' Estimates-Conference Call
- Medtronic Inc Reaffirms FY 2013 Guidance
Latest Key Developments in Medical
- Share this
- Link this
- Digg this
Follow Reuters